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Acute myelogenous leukemia (AML) originates from myeloid stem cells or myeloid 
blasts halted in an immature state during haematopoiesis. AML represents a group of 
heterogeneous forms of myeloid malignancies with diverse genetic abnormalities and 
different stages of myeloid differentiation. The human cell line, HL-60 used in this study 
belongs to a sub-type of AML, namely acute promyelocytic leukemia (APL). Another 
pathologic condition of myeloid expansion is the ”emergency” granulo-monocytopoiesis in 
most of the solid malignancies in which, an army of immature myeloid cells leave the bone 
marrow, called monocytic and granulocytic myeloid-derived suppressor cells (MDSCs). In 
contrast to AML, MDSCs are not malignant cells, but promote angiogensesis and 
immunosuppression leading to the progression of cancer. Both in AML and in solid 
malignancies the differentiation of immature myeloid cells is an already established 
therapeutic concept. 
Since the differentiation of AML cells is frequently followed by apoptosis or increases 
the sensitivity to chemotherapy, we have screened a library of small molecules to mature the 
human prototype cells, HL-60.  
In the resazurin assay small molecules DU192, DU283 and DU325 confounded viability 
of HL-60 cells, half-inhibitory concentration (IC50) values were as follows: 940 nM, 210 nM 
and 20 nM, respectively. IC50 could not be determined for human primary fibroblasts in the 
applied concentration range (1.6 nM - 5 µM). Using flow cytometry we obtained ERK 
phosphorylation as an early response to DU325 stimulation followed by the increase of the 
percentage of the Bcl-xl and pAkt bright cells. The expression of the members of the AP-1 TF 
complex, a driver of cellular differentiation, c-Fos, JunB, c-Jun and JunD were elevated on a 
concentration and time dependent manner detected by qRT-PCR. As a proof of cellular 
differentiation the expression of haematopoietic stem cell markers CD33 and CD34 
decreased. Due to maturation the size and granularity of HL-60 cells increased upon 
treatment. Matured myeloid cell marker CD11b elevated on the cell surface detected by flow 
cytometry. We confirmed that differentiation of HL-60 cells was accompanied by apoptosis. 
We could detect AnnexinV
+
/PI
-
 early and AnnexinV
+
/PI
+
 late apoptotic populations after 24h 
of treatment. Caspase-3 activated gradually by time detected by the percentage of active 
caspase-3 positive cells by flow cytometry and the digestion of zDEVD – amino-Luciferin. 
Finally, as a proof of massive cell death, we have shown the appearance of the hypo-diploid 
apoptotic cells in the sub-G1 population and the leakage of the lactate-dehydrogenase into the 
supernatant. 
We conclude that DU molecules differentiated immature HL-60 cells, which was 
followed by apoptosis. We propose to further investigate the effects of DU325 on additional 
human AML cells obtained from clinical samples. On the other hand we plan to 
systematically investigate the effect of DU325 on the expansion of immature MDSCs in solid 
malignancies. 
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